Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2013

Study Completion Date

October 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim

"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~\- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~\- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."

Trial Locations (3)

38104

University of Tennessee Cancer Institute, Memphis

38120

The West Clinic, Memphis

76104

The Center for Cancer and Blood Disorders, Fort Worth

Sponsors
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Celgene Corporation

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Tennessee Cancer Institute

OTHER

NCT00777673 - Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | Biotech Hunter | Biotech Hunter